Cost-effectiveness of lurbinectedin with atezolizumab for extensive-stage small-cell lung cancer in the United States: impact of drug wastage reduction on economic outcomes

Abstract Background The IMforte trial had supported lurbinectedin as a recommended first-line maintenance therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC), while its cost-effectiveness remains uncertain for patients and clinical decision-makers. This study aims to evaluate...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Jiaming Zhu, Zhengxiong Li, Danlei Song, Wen Liu
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMC 2026-05-01
Seri Bilgileri:	BMC Health Services Research
Konular:	Cost-effectiveness Extensive-stage small-cell lung cancer Lurbinectedin Atezolizumab Drug wastage and mitigation
Online Erişim:	https://doi.org/10.1186/s12913-026-14653-5
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!